Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
Albuquerque, NM, September 24, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announce today that multiple trusts within the South West London Pathology network have chosen the powerful combination of Leica Biosystems Aperio GT 450 DX scanners and Indica Labs’ HALO AP® for digital pathology adoption.
Albuquerque, NM, July 8, 2025 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces that their Pharma Services team is offering quantitative image analysis studies designed and performed to Good Clinical Practice (GCP) standards.
Indica Labs’ Pharma Services Launches GCP-Compliant Image Analysis Service Read More »
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »
Albuquerque, NM and Hørsholm, Denmark, April 9, 2025 – Indica Labs and Visiopharm today announce the successful integration of Visiopharm’s Discovery image analysis software into Indica’s collaborative image management platform, HALO Link. The integration will enable laboratories to create a customized digital pathology ecosystem optimized for their unique image analysis and collaboration needs.
Albuquerque, NM, 8 April 2025 – Indica Labs today announces the launch of the High Dimensional Analysis module for the HALO® image analysis platform. This exciting new functionality for customers in the life sciences enables advanced phenotypic characterization and spatial analysis as well as the exploration of highly multiplexed datasets in either brightfield or fluorescence.
